Azd-4017 clinical trials
Also written AZD4017.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses azd-4017 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD4017
- 7
Studies by the year they started
8 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 3
AstraZeneca (5) · University of Birmingham (1) · University of Oxford (1) · University of Leeds (1)
Studies
Open first, then newest update. How each study uses azd-4017 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.CompletedPhase 2University of BirminghamNCT02017444Written as AZD4017
- Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 InhibitionCompletedPhase 2University of OxfordNCT03111810Written as AZD4017 and prednisolone
- Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)CompletedPhase 2University of LeedsNCT03313297Written as AZD4017
- A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular PressureCompletedPhase 2AstraZenecaNCT01173471Written as AZD4017
- Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose TissueCompletedPhase 1AstraZenecaNCT01096004Written as AZD4017
- Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral DosesCompletedPhase 1AstraZenecaNCT00841048Written as AZD4017
- Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.CompletedPhase 1AstraZenecaNCT00799747Written as AZD4017
- Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017CompletedPhase 1AstraZenecaNCT00791752Written as AZD4017
Codes
What other systems call azd-4017 · ClinicalTrials.gg INT006135
- UNII (FDA) 3JL137394YAZD-4017Confirmed FDA, Wikidata
- Wikidata Q27074744azd-4017Confirmed FDA, Wikidata
- DrugBank DB14875One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3JL137394Y | AZD-4017 | Confirmed FDA, Wikidata |
| Wikidata | Q27074744 | azd-4017 | Confirmed FDA, Wikidata |
| DrugBank | DB14875 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.